A. Pelegrí

520 total citations
12 papers, 211 citations indexed

About

A. Pelegrí is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, A. Pelegrí has authored 12 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in A. Pelegrí's work include Cancer Treatment and Pharmacology (7 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). A. Pelegrí is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). A. Pelegrí collaborates with scholars based in Spain, Chile and United States. A. Pelegrí's co-authors include Juan J. Sirvent, Montserrat Olona, Àngels Arcusa, José Manuel López-Vega, Agustí Barnadas, Emilio Alba, Miguel Martín, Mariela C Aguilar, Cristina Gutiérrez and Jesús Florián and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

In The Last Decade

A. Pelegrí

12 papers receiving 203 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Pelegrí Spain 8 119 98 44 41 34 12 211
D. Perroni Italy 8 141 1.2× 78 0.8× 42 1.0× 11 0.3× 33 1.0× 10 205
Erika Bågeman Sweden 8 129 1.1× 47 0.5× 11 0.3× 66 1.6× 64 1.9× 14 286
Frédérique Mariette Italy 7 101 0.8× 62 0.6× 46 1.0× 85 2.1× 59 1.7× 14 203
Kathi Malone United States 7 120 1.0× 39 0.4× 36 0.8× 51 1.2× 38 1.1× 10 228
Maria Grazia Vitale Italy 7 94 0.8× 52 0.5× 65 1.5× 22 0.5× 57 1.7× 16 221
R Valanzano Italy 8 151 1.3× 51 0.5× 54 1.2× 64 1.6× 50 1.5× 12 331
Qiuxiao Yu China 6 58 0.5× 43 0.4× 49 1.1× 25 0.6× 101 3.0× 11 301
Sibele I. Meireles Brazil 9 94 0.8× 60 0.6× 160 3.6× 35 0.9× 151 4.4× 16 349
Eva Baxter Australia 8 49 0.4× 49 0.5× 25 0.6× 19 0.5× 159 4.7× 10 334
Belén Herráez Spain 6 46 0.4× 63 0.6× 19 0.4× 21 0.5× 68 2.0× 8 133

Countries citing papers authored by A. Pelegrí

Since Specialization
Citations

This map shows the geographic impact of A. Pelegrí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Pelegrí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Pelegrí more than expected).

Fields of papers citing papers by A. Pelegrí

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Pelegrí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Pelegrí. The network helps show where A. Pelegrí may publish in the future.

Co-authorship network of co-authors of A. Pelegrí

This figure shows the co-authorship network connecting the top 25 collaborators of A. Pelegrí. A scholar is included among the top collaborators of A. Pelegrí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Pelegrí. A. Pelegrí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
White, Carole L., Pablo E. Pérgola, Jeff M. Szychowski, et al.. (2013). Blood Pressure After Recent Stroke: Baseline Findings From the Secondary Prevention of Small Subcortical Strokes Trial. American Journal of Hypertension. 26(9). 1114–1122. 28 indexed citations
2.
Dı́ez, Orland, A. Pelegrí, Neus Gadea, et al.. (2011). Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. Oncology Letters. 2(6). 1287–1289. 8 indexed citations
3.
Pelegrí, A.. (2007). Impact of erythropoietin treatment on the quality of life of oncologic patients. Clinical & Translational Oncology. 9(10). 645–651. 7 indexed citations
4.
Pelegrí, A., Lourdes Calvo, Antonio Antón, et al.. (2005). Docetaxel/Gemcitabine Administered Every Other Week as First-Line Treatment for Metastatic Breast Cancer: Final Results of a Phase II Trial. Clinical Breast Cancer. 6(5). 433–438. 21 indexed citations
5.
Sirvent, Juan J., et al.. (2004). Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study.. PubMed. 19(3). 759–70. 30 indexed citations
6.
Pelegrí, A., Lourdes Calvo, José Mayordomo, et al.. (2004). Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial. Seminars in Oncology. 31(2 Suppl 5). 20–24. 15 indexed citations
7.
Bellet, Marina Maria, A. Pelegrí, J. Corominas, et al.. (2004). Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Journal of Clinical Oncology. 22(14_suppl). 752–752. 4 indexed citations
8.
Jara-Sánchez, Carlos, Miguel Martín, José Á. García-Sáenz, et al.. (2003). Vinorelbine as a 96-Hour Continuous Infusion in Heavily Pretreated Patients with Metastatic Breast Cancer: A Cooperative Study by the GEICAM Group. Clinical Breast Cancer. 3(6). 399–404. 13 indexed citations
9.
Alba, Emilio, Nuria Ribelles, A. Antón, et al.. (2003). Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study. Breast Cancer Research and Treatment. 77(1). 1–8. 7 indexed citations
10.
11.
12.
Sirvent, Juan J., et al.. (1974). Caspase-3 and caspase-6 in ductal breast carcinoma: a descriptive study.. PubMed. 21(12). 1321–9. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Perroni Breakdown of academic impact, for papers by Erika Bågeman Breakdown of academic impact, for papers by Frédérique Mariette Breakdown of academic impact, for papers by Kathi Malone Breakdown of academic impact, for papers by Maria Grazia Vitale Breakdown of academic impact, for papers by R Valanzano Breakdown of academic impact, for papers by Qiuxiao Yu Breakdown of academic impact, for papers by Sibele I. Meireles Breakdown of academic impact, for papers by Eva Baxter Breakdown of academic impact, for papers by Belén Herráez
Rankless by CCL
2026